Tailor-Made Pentablock Copolymer Based Formulation for Sustained Ocular Delivery of Protein Therapeutics

Table 3

Coefficient of determination (𝑅²) for various kinetic models for in vitro release of FITC-BSA, IgG, and bevacizumab.

Block copolymers	Korsmeyer-Peppas		Higuchi	Hixson-Crowell	First-order	Zero-order	Best fit model
	𝑅^2	𝑛	𝑅^2	𝑅^2	𝑅^2	𝑅^2
FITC-BSA PB-B NPs	0.989	0.327	0.945	0.905	0.984	0.783	Korsmeyer-Peppas
IgG NPs PB-B NPs	0.982	0.334	0.979	0.979	0.959	0.898	Korsmeyer-Peppas
Bevacizumab PB-B NPs	0.977	0.344	0.969	0.961	0.959	0.881	Korsmeyer-Peppas
FITC-BSA PB-B NPs suspended in gel	0.992	0.549	0.978	0.959	0.982	0.851	Korsmeyer-Peppas
IgG PB-B NPs suspended in gel	0.997	0.818	0.971	0.996	0.987	0.994	Korsmeyer-Peppas